Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program; Says On-Going Collaboration With UCB Remains Highly Productive

Dermira, Inc. DERM, a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the completion of patient enrollment for the global CIMPASI-2 clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. Completion of patient enrollment for this Phase 3 study has triggered a milestone payment of $7.3 million payable by UCB Pharma S.A. to Dermira. Dermira expects to announce topline efficacy and safety data from the CIMZIA Phase 3 clinical development program in 2017, consistent with previous guidance, based on current patient enrollment projections for the two additional, ongoing CIMZIA Phase 3 clinical trials and following completion of the 48-week blinded treatment period in all three trials. CIMZIA is not currently approved for the treatment of psoriasis by any regulatory authority worldwide. "I'm delighted with the completion of patient enrollment in the Phase 3 CIMPASI-2 trial, one of three ongoing Phase 3 studies in our CIMZIA program for adult patients with moderate-to-severe chronic plaque psoriasis," stated Tom Wiggans, chairman and chief executive officer of Dermira. "All patients in this trial have now entered the 48-week treatment portion of the study. More importantly, we remain on track to announce topline results for the CIMZIA Phase 3 clinical program in 2017. Our ongoing collaboration with UCB remains highly productive as we proceed towards our goal of bringing this important potential therapy to the millions of patients with moderate-to-severe plaque psoriasis, a debilitating skin disease. "